Pharma News

Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News | Posted 18/02/2025

Bio-Thera Solutions (Bio-Thera) has partnered with Tabuk Pharmaceutical Manufacturing (Tabuk) to exclusively manufacture, distribute, and market BAT2206, a biosimilar to Stelara (ustekinumab), in Saudi Arabia. Simultaneously, Bio-Thera expanded its collaboration with SteinCares, granting exclusive rights to distribute an additional biosimilar in Latin America, reinforcing its global biosimilar strategy.

Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News | Posted 06/02/2025

Klinge Biopharma (Klinge) and Teva Pharmaceuticals (Teva) formed a semi-exclusive agreement for the commercialization of Formycon’s FYB203 biosimilar to Eylea (aflibercept) in Europe, while MS Pharma partners for the MENA (Middle East and North Africa) commercialization of FYB202, a biosimilar to Stelara (ustekinumab).

Biosimilars thrive as China’s biotech industry gains momentum

Home/Pharma News | Posted 21/01/2025

China is emerging as a global biotech leader, attracting significant investment and partnerships from multinational pharmaceutical companies. Its innovative therapies and biosimilars are gaining international traction, reshaping the industry despite ongoing challenges.

Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News | Posted 15/01/2025

The World Health Organization (WHO) has launched the ‘Greener Pharmaceuticals’ Regulatory Highway’ initiative to promote sustainability in the pharmaceutical sector. The initiative calls for innovative regulatory practices, sustainable manufacturing, and eco-friendly innovations to reduce the environmental impact of healthcare products.

Coherus exits the biosimilars market with sale of Udenyca to Intas Pharmaceuticals

Home/Pharma News | Posted 08/01/2025

On 3 December 2024, Coherus BioSciences announced that it will sell its Udenyca (pegfilgrastim) franchise, a biosimilar version of Amgen’s Neulasta, to India-based drugmaker Intas Pharmaceuticals.

Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement

Home/Pharma News | Posted 20/11/2024

On 31 October 2024, it was announced that Chicago-based Meitheal Pharmaceuticals had expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co, to market and distribute three biosimilars in the US. These include the oncology biosimilars pegfilgrastim and filgrastim, as well as fertility treatment follitropin alpha. 

EMS proposes merger with Hypera to form Brazil's largest drugmaker

Home/Pharma News | Posted 13/11/2024

On 21 October 2024, Brazilian pharmaceutical giant EMS proposed a partnership with competitor Hypera Pharma, setting a course to become Brazil’s largest drug manufacturer.

Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206

Home/Pharma News | Posted 05/11/2024

In October 2024, China based Bio-Thera Solutions (Bio-Thera) and Hungary’s Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to Johnson & Johnson’s Stelara (ustekinumab).

Advances for Biocon Biologics’ Stelara and Eylea biosimilars

Home/Pharma News | Posted 24/09/2024

Biocon Biologics (Biocon) settled patent disputes with Janssen to commercialize Bmab 1200, a biosimilar of Stelara (ustekinumab), in several markets, including Europe and Canada. Additionally, Biocon received UK marketing authorization for Yesafili, its biosimilar of Eylea (aflibercept).

China’s Hasten Biopharma acquires 14 products from Celltrion

Home/Pharma News | Posted 10/09/2024

In July 2024, it was announced that China’s Hasten Biopharmaceutical has acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Korea’s Celltrion.